Skip to content

Journal Article

Prediction Markets in Clinical Trials and Drug Approval

Press Contact: Jason Millman (213)-821-0099

Polymarket logo displayed on a smartphone in front of colorful financial market charts.

(Image / Shutterstock)

Without stronger guardrails, the risks of insider trading and market manipulation outweigh the benefits of prediction markets for drug approvals and clinical trials, Senior Scholar Genevieve Kanter wrote in JAMA Health Forum.

Two well-known prediction markets, Polymarket and Kalshi, allow individuals to place wagers related to Food and Drug Administration actions, while Kalshi and another platform are planning to launch prediction markets for clinical trial results. These markets are relatively small, and the sites do not explain why certain bets are offered or not offered.

As federal regulators develop oversight of these markets, Kanter writes that market operators could consider stronger measures to require disclosure of relevant relationships or forbid trading by those with access to nonpublic information through these relationships.

The full article is available here.